Earnings ·
CONMED reports Q3 sales of $335.6M and raises full-year adjusted EPS guidance to $4.54-$4.61
CNMDCONMED Corp
CONMED Corporation reported third-quarter 2026 net sales of $335.6 million, a decrease of 0.7% year-over-year as reported, but an increase of 6.7% on an organic constant currency basis excluding strategic exits of GI product offerings. Diluted GAAP earnings per share rose to $0.66 from $0.09 in the prior year period, while adjusted diluted EPS was $1.04, down 3.2%. The company updated its full-year 2026 financial guidance, raising the expected range for adjusted diluted EPS to $4.54-$4.61 from a previous estimate of $4.48-$4.60. CONMED operates in the medical device industry, manufacturing and distributing products for minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.